Advanced Regenerative Medicine Naples Fl
239-592-7767
Offering the most advanced Stem Cell, Exosomes and RPA for most any health concerns.
What is RPA?
Regenerative Protein Arrays (RPA) are the “active ingredients” (cytokines, growth factors, miRNA) from all three layers of the placenta, responsible for growth and healing of brain, nerve, soft tissue, organ and musculoskeletal systems.
RPA contains over 80 different cytokines, growth factors and miRNA versus 40 contained in amnio, Wharton’s jelly, bone marrow, PRP, and cord blood combined.
RPA is an acellular, non-biologic product that contains the basic “active ingredients” found in stem cell and exosome products. This eliminates the need for cellular delivery mechanisms; and decreases the potential for a negative reaction, which is possible with cellular products.
How does RPA work?
RPA works by “reprogramming” the local environment, reactivating the cellular processes, and returning the body to the homeostasis of pre-puberty, the peak of the body’s ability to heal.
Where do the placentas come from?
• Regenerative Protein Array (RPA) is only sourced from donors with a 20-year history of no cancer, no systemic disease, and no genetic altering therapies or inoculations (i.e. COVID-19 Vaccination.)
• All donors are screened with lifestyle testing and proven negative for communicable disease via third party, FDA/CLIA certified labs.
• Post-incubation, the product goes through a 4-stage filtering process to remove all cellular tissue, yielding the acellular, non-biologic product you know as RPA.
• The final stage before lyophilization is endotoxin testing, where third party, FDA/CLIA certified labs prove the final product to be “sterile” via meeting the minimum standard of <0.005 EU/mL.
• RPA is produced at FDA registered labs in the United States.
• All donors, tissue, and final product are tested at third party FDA/CLIA certified labs.
Is RPA FDA approved?
• The FDA classifies RPA as a “cell factor” since it is created through an incubation / emission process and is acellular. Therefore, the product is exempt from 21 CFR 1271 biologic regulations.
• The FDA oversees all steps of donation, transport, testing, production, sterilization, and packaging, but treats RPA like a nutraceutical, leaving the choice of use up to the treating physician and patient.
- RPA (Regenerative Protein Array) therapy has shown benefits in treating over 60+ different healthconditions
ranging from chronic pain to degenerative diseases. It is described as a versatile, acellular therapy derived from placental tissue, often utilized by various specialties to address musculoskeletal, neurological, and, in some cases, cosmetic concerns.
- Joint Pain & Arthritis: Effective for osteoarthritis in the knees, hips, shoulders, and wrists, as well as rheumatoid arthritis.
- Spinal Conditions: Used for chronic back pain, degenerative disc disease, and sciatica.
- Soft Tissue Injuries: Treats tendonitis (e.g., rotator cuff, Achilles), ligament tears (e.g., meniscus), and repetitive strain like carpal tunnel syndrome or plantar fasciitis.
- Neurodegenerative Diseases: Ongoing research and anecdotal evidence support its use for Parkinson’s disease, Alzheimer’s, ALS, and Multiple Sclerosis (MS).
- Nerve Issues: Helps with peripheral neuropathy and spinal cord injuries.
- Cognitive Symptoms: Used to treat "brain fog" and fatigue associated with Long COVID or environmental illnesses like mold exposure.
- Autoimmune Disorders: May assist in managing Lupus and Psoriatic Arthritis by modulating the immune response.
- Organ Regeneration: Investigated for supporting liver regeneration (cirrhosis), kidney repair, and heart tissue recovery after a heart attack.
- Complex Pain: Addresses Fibromyalgia and Chronic Fatigue Syndrome.
- Advanced Healing: Applied to severe burns, chronic wounds, and surgical scars.
- Aesthetics: Used for skin rejuvenation, reducing wrinkles, and hair restoration
Comments
Post a Comment